Program Offering and Eligibility

With the LUCENTIS Co-pay Program, eligible, commercially insured patients pay just $5 of their co-pay or co-insurance for LUCENTIS. The program covers the rest of their co-pay or co-insurance, up to $10,000 yearly limit.

There are no income requirements for the LUCENTIS Co-pay Program

Patients are eligible if they:
  • Have been prescribed LUCENTIS for an FDA-approved indication
  • Are 18 years of age or older
  • Have commercial (private or non-governmental) insurance. This includes plans available through state and federal health insurance exchanges
  • Do not receive support from the Genentech® Access to Care Foundation (GATCF) or any independent co-pay assistance foundations
  • Are not a government beneficiary and/or participant in a federal or state-funded health insurance program (eg, Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD, TRICARE)

 

If a patient is not eligible for the LUCENTIS Co-pay Program, there may be other options for co-pay assistance. Call (866) 724-9394 or visit Genentech-Access.com/Lucentis to learn more.

Important Safety Information & Indication

Indication:

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with:

  • Neovascular (wet) age-related macular degeneration (wAMD)
  • Macular edema following retinal vein occlusion (RVO)
  • Diabetic macular edema (DME)
  • Diabetic retinopathy (DR)
  • Myopic choroidal neovascularization (mCNV)

IMPORTANT SAFETY INFORMATION

LUCENTIS is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS. Hypersensitivity reactions may manifest as severe intraocular inflammation.

Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.

Increases in intraocular pressure have been noted both pre-injection and post-injection with LUCENTIS.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

Fatal events occurred more frequently in patients with DME and DR at baseline treated monthly with LUCENTIS compared with control. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded.

In the LUCENTIS Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

For additional safety information, please see LUCENTIS full prescribing information.